In this commentary from The Lancet, the author suggests that COVID-19 is not a pandemic, but a syndemic, which is defined as a set of linked health problems involving two or more afflictions, interacting synergistically, and contributing to excess burden of disease in a population. The syndemic approach reveals biological and social interactions that are […]
In this feature from the British Medical Journal (BMJ), associate editor Peter Doshi explores the emerging research on immunological responses to COVID-19. Is it true that the human population had no pre-existing immunity to SARS-CoV-2? The article attempts to answer this question with a deeper discussion around herd immunity, T cells, antibodies, and more.
One expert credits a “good-enough strategy”; others worry that it will not last. This article explores Sweden’s victory in flattening its curve despite never implementing a full-scale lockdown. Although some claim triumph, others are questioning the cost of the strategy and the nation’s high death toll compared to its Scandinavian neighbors.
As the COVID-19 pandemic uses up health resources, there are a few older diseases that are re-emerging, most notably tuberculosis, HIV, and malaria. Although the cases of these diseases were at their lowest point in 2018, some physicians are fearing that the COVID-19 risks are taking these diseases back to where we were 20 years […]
No effective oral therapy exists for the outpatient treatment of COVID-19. Hydroxychloroquine has in vitro activity against SARS-CoV-2 and has been proposed as a potentially effective treatment. This randomized double-blind, placebo-controlled trial investigated whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.
In this editorial from The Lancet, the authors dissect the 160,000 new cases reported each day worldwide since June 25 and how these numbers illustrate a worrying pattern of the world facing a worsening multipolar pandemic despite the nuanced subnational picture level.
The survey demonstrates the rapid adoption of telemedicine, with 48% of physicians respondents reporting that they are now treating patients through telemedicine, but the pandemic is also creating significant disruption as some physicians are furloughed and others consider practice changes.
Hospitalized patients who had advanced COVID-19 with lung involvement and who received the antiviral agent remdesivir (Gilead Sciences) recovered faster than similar patients who received placebo, according to a preliminary data analysis from a US-led randomized, controlled trial.
According to a recent study published in Journal of Infectious Diseases, an analysis of four different coronaviruses (OC43, 229E, HKU1 and NL63) over an 8-year period demonstrated that they were detected in a limited timeframe, from December to April and May, with a peak during January and February.
Although no proven therapies exist, this JAMA article explores potential treatments for COVID-19 in repurposed drugs (chloroquine and hydroxychloroquine), lopinavir/ritonavir and other antiretrovirals, investigational drugs such as remdesivir, adjunctive therapies, and others.